MTEM Chart
About

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas. On April 20, 2025, Molecular Templates, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap —
Enterprise Value 1.37M Income -15.63M Sales 25.47M
Book/sh — Cash/sh 1.47 Dividend Yield —
Payout 0.00% Employees 62 IPO —
P/E — Forward P/E — PEG —
P/S — P/B — P/C —
EV/EBITDA -0.10 EV/Sales 0.05 Quick Ratio 1.36
Current Ratio 1.56 Debt/Eq 155.07 LT Debt/Eq —
EPS (ttm) — EPS next Y — EPS Growth —
Revenue Growth -91.70% Earnings 2024-08-14 16:00 ROA -37.88%
ROE — ROIC — Gross Margin -14.75%
Oper. Margin -14.50% Profit Margin -61.35% Shs Outstand —
Shs Float 5.67M Short Float 6.45% Short Ratio 0.01
Short Interest — 52W High — 52W Low —
Beta 1.53 Avg Volume — Volume —
Target Price — Recom None Prev Close $0.00
Price $0.11 Change —
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.11
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.11
Low
—
High
—
Mean
—
Insider Transactions
Date Shares Value Url Text Insider Position Transaction Start Date Ownership
0 1279820 845833 — Sale at price 0.66 per share. BIOTECH TARGET N V Beneficial Owner of more than 10% of a Class of Security — 2024-11-14 00:00:00 D
1 175000 332500 — Stock Award(Grant) at price 1.90 per share. LALANDE KEVIN M Director and Beneficial Owner of more than 10% of a Class of Security — 2024-04-02 00:00:00 I
2 250000 475000 — Purchase at price 1.90 per share. BIOTECH TARGET N V Beneficial Owner of more than 10% of a Class of Security — 2024-04-02 00:00:00 D
3 4255319 2000000 — Purchase at price 0.47 per share. BIOTECH TARGET N V Beneficial Owner of more than 10% of a Class of Security — 2023-07-17 00:00:00 D
Financials

No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.

SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Public Trades for MTEM
Date User Asset Broker Type Position Size Entry Price Patterns